Lacidipina Teva

Lacidipine, the active ingredient in Lacidipina Teva, is a calcium channel blocker presented as an oral dosage form for oral use. It treats hypertension in adults.

GNH USA supplies Lacidipina Teva as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacidipine is used to manage high blood pressure by relaxing vascular smooth muscle.

Hypertension: lowers systolic and diastolic blood pressure and reduces cardiovascular strain. Essential hypertension: improves arterial compliance and long‑term blood pressure control. Cardiovascular risk management: contributes to lowering the risk of hypertension‑related complications.

Adverse reactions may occur with any antihypertensive therapy.

Common Side Effects: - Headache - Flushing - Peripheral edema - Dizziness or light‑headedness - Tachycardia - Palpitations

Serious or Rare Side Effects: - Severe hypotension - Acute myocardial infarction - Angina pectoris - Elevated liver enzymes - Allergic skin reactions (rash, pruritus) - Hematologic abnormalities such as neutropenia

Safety considerations should be reviewed before initiating therapy.

Monitor blood pressure regularly: adjust dose based on therapeutic response. Avoid abrupt discontinuation: taper under medical supervision to prevent rebound hypertension. Caution in hepatic impairment: dose may need adjustment. Use with caution in elderly patients: increased sensitivity to hypotensive effects. Avoid concomitant use with strong CYP3A4 inhibitors: may raise plasma levels. Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Potential drug‑drug interactions require clinical awareness.

Major Interactions (Avoid): - Co‑administration with other calcium channel blockers may cause additive hypotension. - Potent CYP3A4 inhibitors (e.g., clarithromycin, itraconazole) can increase lacidipine exposure. - Grapefruit juice: may markedly raise plasma concentrations.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: may enhance bradycardia or hypotensive effects. - Diuretics: risk of excessive blood pressure reduction. - ACE inhibitors or ARBs: monitor for additive antihypertensive effect.